Cardiac amyloidosis has long been one of medicine's underdiagnosed threats — a condition that silently stiffens the heart wall for years before most patients receive a correct diagnosis. Improved imaging tools capable of detecting amyloid deposits earlier and across multiple disease subtypes could meaningfully shift survival curves for a population that is older, increasingly recognized, and poorly served by current diagnostic pathways.
The REVEAL trial is a multicenter, open-label Phase 3 study enrolling adults with suspected cardiac amyloidosis across 18 U.S. centers to evaluate 124I-evuzamitide PET/CT as a diagnostic tool. The radiotracer works through a mechanistically distinctive approach: rather than targeting a specific precursor protein such as transthyretin or light chain, evuzamitide binds hypersulfated heparan sulfate glycans embedded within amyloid fibrils themselves — a structural feature common across amyloid subtypes. This pan-amyloid binding strategy is the compound's central scientific proposition. Imaging is performed approximately four hours post-injection at a 1.0 mCi dose, with potassium iodide co-administration to limit thyroid radioiodine exposure. Three blinded nuclear cardiology readers independently assess myocardial uptake, while a separate panel of three amyloidosis specialists adjudicate ground-truth diagnoses using a broad standard-of-care dataset including biopsy, cardiac MRI, echocardiography, and genetic data.
The broader context matters here. Technetium-99m bone scintigraphy already provides reasonable sensitivity for ATTR cardiac amyloidosis but performs poorly for AL subtype. A subtype-agnostic PET tracer with validated Phase 3 evidence would fill a genuine clinical gap, particularly in patients presenting with unexplained heart failure with preserved ejection fraction — a population where amyloidosis prevalence is increasingly recognized as substantial. Key limitations at this stage are structural: REVEAL is single-arm without a head-to-head comparator, and the diagnostic truth standard depends on multi-modal adjudication rather than a single gold-standard biopsy across all participants. This is a trial design and rationale paper, meaning efficacy data remain pending. Still, the fibril-targeting mechanism and Phase 3 scale make this a genuinely consequential study to watch.